एवरोलिमस के इंटरैक्शन

• taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.5) , Warnings and Precautions (5.5) , Drug Interactions (7.1) ] . (अल्प्राज़ोलम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…(Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ]. with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . in… (अल्फुज़ोसिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

…bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (आइवाब्राडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

• Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (इरिनोटेकन लेबल, दवाओं के इंटरैक्शन)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (उपाडासिटिनिब लेबल, दवाओं के इंटरैक्शन)

UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (उब्रोजेपेंट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (एकालाब्रुटिनिब लेबल, दवाओं के इंटरैक्शन)

VYTORIN is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (एज़ेटिमाइब और सिमवास्टेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (एडालिमुमैब लेबल, बॉक्स्ड चेतावनी)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . (एपिक्साबैन लेबल, दवाओं के इंटरैक्शन)

…Patients Eplerenone is contraindicated in all patients with: • serum potassium > 5.5 mEq/L at initiation, • creatinine clearance ≤ 30 mL/min, or • concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1) , Clinical Pharmacology (12.3)… (एप्लेरेनोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (एर्गोटामिन और कैफीन लेबल, बॉक्स्ड चेतावनी)

Avoid co-administering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin). (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

• Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. (एलेट्रिप्टान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant use of almotriptan tablets and potent CYP3A4 inhibitors should be avoided in patients with renal or hepatic impairment [see Clinical Pharmacology ( 12.3 )] . (एल्मोट्रिप्टान लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (एवानाफिल लेबल, दवाओं के इंटरैक्शन)

Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS ). (एस्टाज़ोलम लेबल, चेतावनियां)

Cytochrome P450 3A4 Interaction The concomitant use of Oxycodone Hydrochloride Oral Solution with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of oxycodone hydrochloride tablets with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology… (कैबोज़ैंटिनिब लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (कोडीन लेबल, बॉक्स्ड चेतावनी)

Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [see Drug Interactions (7) ] . (कोल्चिसिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (टैक्रोलिमस लेबल, बॉक्स्ड चेतावनी)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [see Warnings and Precautions (5.1) ] . (टोरेमिफेन लेबल, बॉक्स्ड चेतावनी)

…dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2) ] Unable to sense or respond to thirst Hypovolemic hyponatremia Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5) ] Anuria Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product [see Adverse… (टोल्वैप्टन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Strong CYP 3A Inhibitors Triazolam is contraindicated in patients receiving strong inhibitors of CYP 3A such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir [see Contraindications (4) , Drug Interactions (7.1) ] . (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (ट्रेटिनोइन लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 ) (ट्रैबेक्टेडिन लेबल, दवाओं के इंटरैक्शन)

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (डाइहाइड्रोएर्गोटामिन लेबल, बॉक्स्ड चेतावनी)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (डारुनाविर लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of strong CYP3A4 inhibitors. (डासाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

If serotonin syndrome occurs, discontinue dextroamphetamine sulfate and the CYP2D6 inhibitor [see Warnings , Overdosage ]. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

QT Prolongation: Monitor ECG if concomitant use of drugs that prolong QT interval cannot be avoided or if concomitant CYP3A4 inhibitors used. (डेक्सट्रोमेथॉर्फन और क्विनिडिन लेबल, चेतावनियां और सावधानियां)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (डेक्सामेथासोन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inhibitors: Avoid concomitant use. (डैरिडोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp. (डॉक्सोरूबिसिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Drug-Drug Interactions Strong Inhibitors of Cytochrome P450 (CYP) 3A4 Tamsulosin-containing products, including JALYN, should not be coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole) as this can significantly increase tamsulosin exposure [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ]. (ड्यूटास्टेराइड और टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (थायोटेपा लेबल, दवाओं के इंटरैक्शन)

Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology… (नालोक्सेगोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Therefore, the concomitant administration of NYMALIZE and strong CYP3A4 inhibitors should generally be avoided [ see Warnings and Precautions (5.3) ]. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors and inducers : SULAR is substrate of CYP3A4 and coadministration of SULAR with any known inducer or inhibitor of CYP3A4 should be avoided in general. (निसोल्डिपिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

Concomitant use of pimozide with paroxetine and other strong CYP 2D6 inhibitors is contraindicated (See PRECAUTIONS – DRUG INTERACTIONS ). (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Cytochrome P450 3A4 Interaction The concomitant use of DEMEROL Injection with all cytochrome P450 3A4 inhibitors may result in an increase in meperidine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

CYP3A4 Inhibitors Doses of Toviaz greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration (2.5) ]. (फेसोटेरोडिन लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (फ्लुटिकासोन लेबल, दवाओं के इंटरैक्शन)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (फ्लुड्रोकॉर्टिसोन लेबल, चेतावनियां)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (फ्लुनिसोलाइड लेबल, सावधानियां)

Concomitant administration of BIXLENVO with combined P-gp, UGT1A1, and strong CYP3A inhibitors is not recommended. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (बोसुटिनिब लेबल, दवाओं के इंटरैक्शन)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (बोसेंटन लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors Monitor patients closely when the combination use of CYP2D6 inhibitor and metoprolol cannot be avoided. (मेटोप्रोलोल लेबल, दवाओं के इंटरैक्शन)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (मेथएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The concomitant use of METHADOSE with all cytochrome P450 3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

SELZENTRY is contraindicated in patients with severe renal impairment or ESRD (creatinine clearance [CrCl] less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions ( 5.3 )]. (मैराविरोक लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (मैसिटेंटन लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (रिमेजेपेंट लेबल, दवाओं के इंटरैक्शन)

Use with P-gp and Strong CYP3A Inhibitors or Inducers Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A inhibitors [see Drug Interactions (7.2) ] . (रिवारोक्साबैन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

If concomitant use of VYVANSE with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate VYVANSE with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (लिसडेक्सएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inhibitors: Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. (लैरोट्रेक्टिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (लोमिटापाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (लोरलाटिनिब लेबल, दवाओं के इंटरैक्शन)

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and cobicistat-containing products) (see WARNINGS , Myopathy/Rhabdomyolysis ). (लोवास्टेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions ( 7.1 )]. (ल्यूरासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (विन्क्रिस्टिन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Avoid alcohol-, hydrogen peroxide-, iodine-, or thyme- containing products, as they may exacerbate the condition. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

ZOCOR is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (सिमवास्टेटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Severe renal impairment (CCr < 30 mL/min) Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS (7.1) ] Patients with a history of hypersensitivity to silodosin or any of the ingredients in silodosin capsules… (सिलोडोसिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . (सुज़ेट्रिजिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

सेंट जॉन्स वॉर्ट इन दवाओं के टूटने की रफ़्तार बढ़ाकर इन्हें कमज़ोर कर सकता है, जिसका मतलब अंग की अस्वीकृति (रिजेक्शन), खून के थक्के या असर का खत्म होना हो सकता है। (NCCIH, St. John's Wort)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

The dosage of Solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )] . (सोलिफेनासिन लेबल, दवाओं के इंटरैक्शन)

Cytochrome P450 3A4 Interaction The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Bitartrate and Ibuprofen Tablets with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and homatropine methylbromide with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

• CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (आइफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

When treating patients, consideration of whether to use RENFLEXIS alone or in combination with other immunosuppressants such as azathioprine or 6-mercaptopurine should take into account a possibility that there is a higher risk of HSTCL with combination therapy versus an observed increased risk of immunogenicity and hypersensitivity reactions with infliximab… (इन्फ्लिक्सिमैब लेबल, चेतावनियां और सावधानियां)

The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor. (इलोपेरिडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4/5 Inhibitors Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. (एक्सिटिनिब लेबल, दवाओं के इंटरैक्शन)

Use of Cytochrome P450 3A4 Inhibitors Ritonavir and other strong cytochrome P450 3A4 (CYP3A4) inhibitors can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )] . (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma estrogen and/or progestin concentrations. (एटोनोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors Prevention or Management With concomitant use of atomoxetine oral solution and a strong CYP2D6 inhibitor 1 , increase the titration interval [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] . (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

LIPITOR plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. (एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Drugs Inducing or Inhibiting CYP3A Enzymes Rilpivirine is primarily metabolized by cytochrome P450 (CYP) 3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of RPV [see Contraindications (4) , Warnings and Precautions (5.7) , and Clinical Pharmacology (12.3) ] . (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. (एम्लोडिपिन और ओल्मेसार्टन लेबल, दवाओं के इंटरैक्शन)

Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors and CYP3A4 Inhibitors : See full prescribing information for ABILIFY MAINTENA dosage modifications when used concomitantly with CYP2D6 inhibitors and/or CYP3A4 inhibitors for greater than 14 days ( 7.1 ) (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects. (एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

…exposure at steady state. [See Clinical Pharmacology (12.3).] Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem,… (एस्ट्राडियोल और डायनोजेस्ट लेबल, दवाओं के इंटरैक्शन)

Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. (एस्ट्राडियोल और नॉरएथिस्टेरोन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (ऑक्सीब्यूटिनिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, दवाओं के इंटरैक्शन)

Risk of Use in Patients with Decreased Cytochrome P450 2D6 Function or Concomitant Use or Discontinuation with Cytochrome P450 3A4 Inhibitors and Inducers Risk of Increased Oliceridine Plasma Concentrations Increased plasma concentrations of oliceridine, which may result in prolonged opioid adverse reactions and exacerbated respiratory depression, may occur when… (ओलिसेरिडिन लेबल, चेतावनियां और सावधानियां)

Inhibitors of CYP2D6 Fluoxetine: Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. (ओलैंज़ापिन लेबल, दवाओं के इंटरैक्शन)

The Effect of Other Drugs on Olanzapine — Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount [see Clinical Pharmacology ( 12.3 )]. (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the mometasone furoate plasma concentration and potentially increase the risk for adverse reactions. (ओलोपाटाडीन और मोमेटासोन लेबल, दवाओं के इंटरैक्शन)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Cannabidiol oral solution : Reduce the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Drug Interactions with VRAYLAR Strong or Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of VRAYLAR with a strong or moderate CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone [see Clinical Pharmacology ( 12.3 ) ]. (कैरिप्राज़िन लेबल, दवाओं के इंटरैक्शन)

Inhibitors of CYP3A4 and CYP3A5 Inhibitors of CYP3A4 and/or CYP3A5 may increase plasma concentrations of clindamycin [ see Clinical Pharmacology (12.3) ]. (क्लिंडामाइसिन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 and CYP3A4 Inhibitors Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology ( 12.3 )] . (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Although a causal relationship between a specific drug and the arrhythmia was not established in this case, erythromycin is a CYP3A4 inhibitor and has been shown to increase quinine plasma levels when used concomitantly. (क्विनीन लेबल, चेतावनियां और सावधानियां)

• Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one‑sixth when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ( 2.5 , 7.1 , 12.3 ) (क्वेटियापिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

ग्रेपफ्रूट का जूस ट्रांसप्लांट के बाद अंग की अस्वीकृति (रिजेक्शन) रोकने वाली दवाओं का खून में स्तर बढ़ाता है। (FDA, Grapefruit Juice and Some Drugs Don't Mix)

…Interactions: Effect of other Drugs on INTUNIV Concomitant Drug Name or Drug Class Clinical Rationale and Magnitude of Drug Interaction Clinical Recommendation Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase… (ग्वानफेसिन लेबल, दवाओं के इंटरैक्शन)

As zafirlukast is known to be an inhibitor of CYP3A4 in vitro , it is reasonable to employ appropriate clinical monitoring when these drugs are coadministered with zafirlukast. (ज़ाफिरलुकास्ट लेबल, सावधानियां)

Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C max of ziprasidone by about 35 to 40%. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. (ज़ोल्पिडेम लेबल, दवाओं के इंटरैक्शन)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine) and timolol. (टिमोलोल लेबल, दवाओं के इंटरैक्शन)

• Do not exceed 50 mg/day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine). (टेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

…Physicians should be aware that CIALIS for once daily use provides continuous plasma tadalafil levels and should consider this when evaluating the potential for interactions with medications (e.g., nitrates, alpha-blockers, anti-hypertensives and potent inhibitors of CYP3A4) and with substantial consumption of alcohol [see Drug Interactions ( 7.1 , 7.2 , 7.3 )] . (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Interactions Affecting XELJANZ/XELJANZ XR When Concomitantly Used with Other Drugs Strong CYP3A4 Inhibitors (e.g., ketoconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Moderate… (टोफासिटिनिब लेबल, दवाओं के इंटरैक्शन)

Drug Interactions CYP3A4 Inhibitors Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions ). (टोल्टेरोडिन लेबल, दवाओं के इंटरैक्शन)

Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with KENALOG-40 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. (ट्रायमसिनोलोन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of dexlansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (डेक्सलैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (डेनोसुमैब लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA ( 7.1 ) (डेफ्लाज़ाकॉर्ट लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors The systemic exposure of darifenacin from darifenacin extended-release tablets is increased in the presence of CYP3A4 inhibitors. (डैरिफेनासिन लेबल, दवाओं के इंटरैक्शन)

Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (डॉक्साज़ोसिन लेबल, दवाओं के इंटरैक्शन)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. (डोराविरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Monitor for increased dronabinol-related adverse reactions when dronabinol oral solution is co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice). (ड्रोनाबिनोल लेबल, दवाओं के इंटरैक्शन)

Consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (निंटेडानिब लेबल, दवाओं के इंटरैक्शन)

…as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact : Increased exposure of esomeprazole [see Clinical Pharmacology (12.3) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

…Astemizole, Cisapride, and Pimozide Interactions Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. (नेफाज़ोडोन लेबल, चेतावनियां)

Use with CYP2D6 Inhibitors Nebivolol exposure increases with inhibition of CYP2D6 [see Drug Interactions ( 7 ) ] . (नेबिवोलोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase the systemic concentrations of progestins, including norethindrone. (नॉरएथिस्टेरोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. (नॉरएथिस्टेरोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (नॉरएल्जेस्ट्रोमिन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (नॉरजेस्टिमेट और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of CYP3A4 inhibitors such as itraconazole, fluconazole, grapefruit juice or ketoconazole may increase plasma hormone concentrations. (नॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3) ] . (पाल्बोसिक्लिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inhibitors: Reduce NUPLAZID dose to 10 mg once daily. (पिमावैनसेरिन लेबल, दवाओं के इंटरैक्शन)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (पेनिसिलामिन लेबल, चेतावनियां)

Exposure of Paricalcitol Injection will increase upon coadministration with strong CYP3A inhibitors [see Clinical Pharmacology (12.3) ] . (पैरिकैल्सिटोल लेबल, दवाओं के इंटरैक्शन)

Effects of Other Drugs on the Pharmacokinetics of Primaquine Strong CYP2D6 Inhibitors Published clinical and non-clinical reports indicate reduced CYP2D6 activity may decrease the formation of active metabolites of primaquine, which may reduce antimalarial efficacy of Primaquine phosphate Tablets (see CLINICAL PHARMACOLOGY, Pharmacogenomics ). (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (प्रेडनिसोन लेबल, दवाओं के इंटरैक्शन)

CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when co-administered with INNOPRAN XL. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (फेनोफाइब्रिक एसिड लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (फेनोफाइब्रेट लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Coadministration of CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several-fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism. (फेलोडिपिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Antineoplastics: Dasatinib, nilotinib, ibrutinib, vinblastine, everolimus ↑Antineoplastics Fosamprenavir calcium or fosamprenavir calcium /ritonavir may increase plasma concentrations of antineoplastics metabolized by CYP3A, potentially increasing the risk of adverse events typically associated with these medications. (फोसएम्प्रेनाविर लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (बुडेसोनाइड लेबल, चेतावनियां और सावधानियां)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (बेंडामुस्टिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (बोर्टेज़ोमिब लेबल, दवाओं के इंटरैक्शन)

Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual tablet is achieved. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (मर्कैप्टोप्यूरिन लेबल, चेतावनियां और सावधानियां)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (माइकोफेनोलेट लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (मिडाज़ोलम लेबल, दवाओं के इंटरैक्शन)

…mifepristone is contraindicated. [See Contraindications (4.3)] 5.6 Use of Strong CYP3A Inhibitors Mifepristone should be used with caution in patients taking ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, clarithromycin, conivaptan, lopinavir/ritonavir, posaconazole,… (मिफेप्रिस्टोन लेबल, चेतावनियां और सावधानियां)

Examples phenytoin, carbamazepine, rifampin Strong CYP3A Inhibitors Clinical Impact The concomitant use of strong CYP3A inhibitors with REMERON/REMERONSolTab may increase the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

• Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine) : See Full Prescribing Information for recommended dosage reductions. (मेटोक्लोप्रामाइड लेबल, दवाओं के इंटरैक्शन)

CYP2D6 inhibitors: Increased metoprolol concentration. (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Ketoconazole (Potent Inhibitor of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine with 400 mg of ketoconazole once daily for 10 days in 8 healthy volunteers resulted in an increase in the mean C max and AUC of mefloquine by 64% and 79%, respectively, and an increase in the mean elimination half-life of mefloquine from 322 hours to 448 hours. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (मोमेटासोन लेबल, चेतावनियां और सावधानियां)

Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone,… (यूमेक्लिडिनियम और विलैंटेरोल लेबल, चेतावनियां और सावधानियां)

Increase in Plasma Concentrations of ella Associated with Co-Administered Drugs CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella [see Pharmacokinetics (12.3) ] . (यूलिप्रिस्टल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (रक्सोलिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Coadministration of EDURANT or EDURANT PED and drugs that inhibit CYP3A may result in increased plasma concentrations of rilpivirine. (रिल्पिविरिन लेबल, दवाओं के इंटरैक्शन)

Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

CYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co‑administered. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (रैमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in vivo plasma clearance of ropivacaine. (रोपिवाकेन लेबल, दवाओं के इंटरैक्शन)

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (रोफ्लुमिलास्ट लेबल, दवाओं के इंटरैक्शन)

• Monitor for toxicities related to increased romidepsin exposure when co-administering romidepsin with strong CYP3A4 inhibitors ( 7.2 ). (रोमिडेप्सिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (लुमाटेपेरोन लेबल, दवाओं के इंटरैक्शन)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (लेफ्लुनोमाइड लेबल, चेतावनियां और सावधानियां)

CYP3A inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice The effect of grapefruit juice on CYP3A4 enzymes (e.g., strong vs. moderate inhibition) depends on its brand, concentration, and preparation. , or ketoconazole may increase systemic exposure of the estrogen and/or progestin component of CHCs. (लेवोनॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (लेवोमिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (लैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (लैकोसामाइड लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. (लोपेरामाइड लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. (वारफेरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Drug Interactions with Strong or Moderate CYP3A4 Inhibitors Concomitant administration with strong CYP3A4 inhibitors (such as ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (such as erythromycin) increases plasma concentrations of vardenafil. (वार्डेनाफिल लेबल, चेतावनियां और सावधानियां)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (वाल्बेनाज़िन लेबल, चेतावनियां और सावधानियां)

Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions ( 7.1 ) (विनोरेल्बिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors: The VIIBRYD dose should not exceed 20 mg once daily when co-administered with strong CYP3A4 inhibitors ( 2.4 , 7 ). (विलाज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Substrates Clinical Impact Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered [see Clinical Pharmacology (12.3) ] . (विलोक्साज़िन लेबल, दवाओं के इंटरैक्शन)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

• Strong inhibitors of CYP2D6: Reduce TRINTELLIX dose by half when coadministered ( 2.5 , 7.1 ). (वोर्टियोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

In a drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. (सिक्लेसोनाइड लेबल, दवाओं के इंटरैक्शन)

Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet. (सिनाकैल्सेट लेबल, दवाओं के इंटरैक्शन)

Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. (सिलोस्टाज़ोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (सिल्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (सैक्साग्लिप्टिन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (सैक्साग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of inhibitors of CYP3A4 may lead to increases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions associated with the use of excessive doses. (हाइड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

The effect of CYP3A4 inhibition and of decreased CYP2D6 enzyme may be additive. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Cannabidiol oral solution : Reduce the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

TAF is a weak inhibitor of CYP3A in vitro . (एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

However, no formal drug-drug interaction studies between zileuton and CYP3A4 inhibitors, such as ketaconazole, have been conducted. (ज़ाइल्यूटॉन लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. (डाइसोपाइरामाइड लेबल, दवाओं के इंटरैक्शन)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (ड्यूटास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (पिटावास्टेटिन लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (प्रवास्टेटिन लेबल, चेतावनियां और सावधानियां)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (प्रोपाइलथायोयूरेसिल लेबल, चेतावनियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

An in vitro study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4 enzymes. (फैमसिक्लोविर लेबल, दवाओं के इंटरैक्शन)

Additionally, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. (फ्लुओक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (फ्लुवास्टेटिन लेबल, चेतावनियां और सावधानियां)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

• CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). (मेक्लिज़िन लेबल, दवाओं के इंटरैक्शन)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (मेथिमाज़ोल लेबल, चेतावनियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (रोसुवास्टेटिन लेबल, चेतावनियां और सावधानियां)

Effect of SUNLENCA on Other Drugs Lenacapavir is a moderate inhibitor of CYP3A. (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (सर्ट्रालिन लेबल, दवाओं के इंटरैक्शन)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

CYP2D6 substrates Clinical Impact: In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. (सेविमेलिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroids may be indicated until clinical symptoms resolve. (एवरोलिमस लेबल, चेतावनियां और सावधानियां)

Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (डेसलोराटाडीन लेबल, दवाओं के इंटरैक्शन)